Your browser doesn't support javascript.
loading
Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.
Kasichayanula, Sreeneeranj; Liu, Xiaoni; Zhang, Weijiang; Pfister, Marc; LaCreta, Frank P; Boulton, David W.
Affiliation
  • Kasichayanula S; Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb Co, Princeton, NJ, USA.
Clin Ther ; 33(11): 1798-808, 2011 Nov.
Article in En | MEDLINE | ID: mdl-22030444
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Sodium-Glucose Transport Proteins / Glucosides / Hypoglycemic Agents / Liver Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Clin Ther Year: 2011 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Sodium-Glucose Transport Proteins / Glucosides / Hypoglycemic Agents / Liver Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Clin Ther Year: 2011 Type: Article Affiliation country: United States